WEALTHMAKERS.COM: Issues Research Reports on AMAT, CTIC, JIVE, MRVL, PSTI, REGN
(M2 PressWIRE Via Acquire Media NewsEdge) WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued new research reports today on the following stocks: Applied Materials (NASDAQ: AMAT), Cell Therapeutics (NASDAQ: CTIC), Jive Software (NASDAQ: JIVE), Marvell Technology (NASDAQ: MRVL), Pluristem Therapeutics (NASDAQ: PSTI) and Regeneron Pharmaceuticals (NASDAQ: REGN).
Click here to download each report:
WealthMakers is powered by WOPR (WealthMakers Online Predictive Research), www.wopronline.com , a military-style computer that uses parallel processing, genetic algorithms, neural networks and unbridled computing power to analyze exactly what event ( technicals, fundamentals, earnings, seasonality, short squeeze, group rotation, chart patterns, insider buying/selling and multiple other factors) will move each stock, in which direction, to what % degree, in the specific amount of time and with what degree of probability. Based on IBMs work on Deep Blue (now called "Watson"), this powerful database technology matched with hundreds of data feeds and the ability to find patterns, that humans cannot, has the ability to do the work of hundreds or thousands of analysts without getting tired (24 hours per day / 7 days per week). Our unparalleled technology, trading algorithms and proprietary data generate confident predictions, with clear and concise objectives resulting in unique and innovative research reports that move markets and create exponential returns to our clients.
Click here to LIKE us on Facebook:
Click here to FOLLOW us on Twitter:
Click here to access WealthMakers technology:
Users access these powerful research reports though the PowerTrader Matrix. The Matrix automatically scans through 14,000 stocks, 11 strategies and real-time price updates to find only those stocks that have multiple predictions, at the same time, in the same direction, with no conflicting predictions and the fundamental value of the stock is in-line with the direction of the trade. This powerful technology filters out the exact long/short trades that our trading network need to enter at the precise time and price that they should be entered /exited.
To learn more click here: www.buyins.com/woprbrochure.pdf
WealthMakers Power Trader works because the Market Read strategies have a very high success rate. Both "accuracy" and "average return" and "average # of days in trade" are tracked in real-time and documented at www.buyins.com/images/stats.pdf
Applied Materials, Inc. (NASDAQ: AMAT) provides manufacturing equipment, services, and software to the semiconductor, flat panel display, solar photovoltaic (PV), and related industries worldwide. The company's Silicon Systems Group segment offers a range of manufacturing equipment used to fabricate semiconductor chips or integrated circuits. This segment provides systems that perform primary processes used in chip fabrication, including atomic layer deposition, chemical vapor deposition, physical vapor deposition, electrochemical deposition, rapid thermal processing, chemical mechanical planarization, wet cleaning, and wafer metrology and inspection, as well as systems that etch or inspect circuit patterns on masks used in the photolithography process. Its Applied Global Services segment offers products and services designed to enhance the performance and productivity, and reduce the environmental impact of the fab operations of semiconductor, liquid crystal displays (LCDs), and solar PV manufacturers. The company's Display segment provides products for manufacturing thin film transistor LCDs for televisions, personal computers (PCs), tablet PCs, smartphones, and other consumer-oriented electronic applications. Its Energy and Environmental Solutions segment offers manufacturing systems for the generation and conservation of energy, as well as manufacturing solutions for wafer-based crystalline silicon applications. This segment also provides roll-to-roll vacuum Web coating systems for deposition of a range of films on flexible substrates for functional, aesthetic, or optical properties; and roll-to-roll machine for depositing ultra-thin aluminum films for flexible packaging applications. The company serves manufacturers of semiconductor wafers and chips, flat panel LCDs, solar PV cells and modules, and other electronic devices. Applied Materials, Inc. was founded in 1967 and is headquartered in Santa Clara, California.
Cell Therapeutics, Inc. (NASDAQ: CTIC) engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is developing Pixuvri, a novel anthracycline derivative for the treatment of hematologic malignancies and solid tumors; OPAXIO, a chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate for treating ovarian, brain, esophageal, head, and neck cancers; Brostallicin, a synthetic DNA minor groove binding agent; and Bisplatinates, a platinum-based chemotherapy drug to treat various cancers. The company, in collaboration with Chroma Therapeutics, Ltd., is also engaged in developing Tosedostat, an oral aminopeptidase inhibitor. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.
Jive Software, Inc. (NASDAQ: JIVE) provides a social business software platform to businesses, government agencies, and other enterprises. Its Jive Engage Platform enables collaboration across two principal communities and employees within the enterprise, and customers and partners outside the enterprise. The company's Jive Engage Platform is used as a communications tool and collaborative workspace that supports and enhances knowledge sharing, facilitates communication within and across organizational boundaries, and enables individuals to work together to achieve common business goals. Its platform allows customers and partners of the enterprise to connect socially with one another, as well as with the enterprise, in a structured online community that enables users to ask questions, post answers, and communicate about a product or particular issue. The company's solution also taps into the social Web by integrating relevant content and connections across the social networking landscape, enabling enterprises to enhance their interactions with customers, leverage feedback to deliver improved products and services, and respond quickly to market opportunities. In addition, it provides Jive What Matters, a user interface to track, consume, manage, and filter critical business information, communications, and actions; Jive Apps Market, a secure market of business applications that are integrated to and accessed from within the Jive Engage Platform; and professional, support, and training services. The company sells its products and solutions through direct sales organization, resellers, outsourcing vendors, and system integrators. It serves customers in various industries, including consulting services, education, financial services, healthcare, life sciences, manufacturing, retail, telecommunications, and technology in the United States, South America, and Europe. Jive Software, Inc. was founded in 2001 and is headquartered in Palo Alto, California.
Marvell Technology Group Ltd. (NASDAQ: MRVL) designs, develops, and markets analog, mixed-signal, digital signal processing, and embedded and standalone ARM-based microprocessor integrated circuits. It offers mobile and wireless products comprising communications processors; modem processors; Wi-Fi and other communication protocols, including Bluetooth and/or FM; mobile computing products; and connected home computing products. The company also provides a range of integrated data storage products, including hard disk drive, solid-state drive, hybrid hard disk drive, and optical disk drive controllers, as well as storage-system products. In addition, it offers networking products comprising cloud infrastructure products for home, private, and public cloud networks; and service provider infrastructure, including residential fiber access infrastructure and mobile Internet infrastructure, as well as the transition to intellectual property radio access networks. Further, the company provides printing ASIC products; digital video processing products; power management and green technology products, such as DSP switcher integrated regulators, analog switching regulators, and integrated power management IC products; and Smart-LED Lighting platform, as well as Smart Energy Platform driven by a Wi-Fi enabled microcontroller and integrated software. It operates in the United States, Canada, China, Germany, Hong Kong, India, Israel, Italy, Japan, Korea, Malaysia, the Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, and the United Kingdom. Marvell Technology Group Ltd. was founded in 1995 and is headquartered in Hamilton, Bermuda.
Pluristem Therapeutics Inc. (NASDAQ: PSTI), a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company's products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of serious medical conditions in the United States. The company's commercial products include EYLEA (aflibercept) Injection for the treatment of neovascular age-related macular degeneration; and ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consists of EYLEA for the treatment of serious eye diseases; ZALTRAP (Aflibercept), which is developed in oncology; and ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment. The company's earlier stage clinical programs include various human monoclonal antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction; REGN88 for rheumatoid arthritis; REGN668 for atopic dermatitis and eosinophilic asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; REGN846 for atopic dermatitis; and REGN728, REGN1033, and REGN1154. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize ZALTRAP and EYLEA. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Wealthmakers Online Predictive Research (WOPR) is a distributed computing system that has hundreds of data feeds (economic, weather, geopolitical, interest rates, energy, equities, currencies, commodities, etc.) feeding into a relational database that searches for patterns and determines how a trading instrument has behaved both before and after specific events have taken place in the past. Only about 25% of stocks display patterns at any given time and only about 1% of stocks exhibit all the necessary conditions on any given day to make a trade. That means that out of 14,000 stocks, only about 140 trades are high probability trades that our system would generate a research report on and disseminate the information to clients. This process eliminates the noise and only tells you which stocks have multiple strategies lining up at the same time, in the same direction, with no conflicting predictions and the fundamental valuation is in-line with the prediction!
EARNINGS - Most stock price histories show random or unpredictable movements around earnings reports. But some repeat the same pattern quarter after quarter, year after year. Earnings predict probability, price move and length of move before and after all US stock earnings reports.
FRICTION FACTOR - Friction Factor is based on the relationship between the price of a stock and the volume at which it's bought and sold. Normal and abnormal Friction factor patterns can help you time your buying and selling decisions for maximum earnings potential.
GATS - The Global Automated Trading System (GATS) combines neural networks and genetic algorithms to reduce investment risks. GATS selects the highest probability trades in stocks, bonds, options, commodities, currencies and private equities, delivering precise, predictive and profitable data.
GROUP SECTOR - Certain institutions can exert buying or selling pressure over an entire industry group, pushing prices higher. Group Sector identifies stocks that most closely match their group's movement and generate powerful group consensus trading signals to help you profit from the herd mentality.
PATTERN SCANNER - describes the current technical situation in your stock. It displays the technicals, trend conditions and seasonal factors and automatically discovers how that stock has performed in the trading days following the occurrences of the event or combination of events. This technology automatically scans using complex historical queries based on what event is taking place right now in the stock. It then displays the probability, expected return and number of trading days for the expected move.
EVENTS - This technology automatically tracks "Trigger Events" that positively or negatively affect the value of a stock - or its perceived value among analysts - ranging from price fluctuations to natural disasters and political shifts. The results reveal patterns that can predict market movements.
RegSHO NAKED SHORTS - SEC Regulation SHO mandates that if a clearing agent holds a fail-to-deliver position for 13 consecutive settlement days, it must purchase securities to close out its position, a.k.a. a forced cover. WealthMakers aggregates data from NYSE, AMEX, NASDAQ, OTCBB and PINKSHEETS to track stocks that are about to have forced covers.
SEASONALITY - Seasonality analyzes more than 20 years of data to determine if stocks have a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias.
SQUEEZETRIGGER - Our proprietary database of more than 3,500,000,000 short sale transactions allows us to calculate the exact price at which the total short interest is short in each stock. Squeeze Trigger Alerts let you know exactly when a short squeeze will start and how to trade profitably.
VALUATION - A stock's value is a function of its forecasted earnings per share and forecasted earnings growth, as well as profitability, interest and inflation rates. Valuation use these metrics to determine at what price a stock is undervalued or overvalued, so that you can make investment decisions accordingly.
INSIDER - Significant stock sales or purchases by company "insiders" (officers or directors) can be a predictor of future price movements, up or down. The Insider strategy tracks these actions and correlates them with historical data to give you an investment edge.
WEALTHMAKERS is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. WEALTHMAKERS has not been compensated by any of the above mentioned companies specifically for this report. Past performance is not indicative of future results. Please visit our web site, www.wealthmakers.com , for complete risks and disclosures.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to firstname.lastname@example.org)).
(c) 2012 M2 COMMUNICATIONS
[ InfoTech Spotlight's Homepage ]